Dual or Mono Antiplatelet Therapy for Patients with Acute Ischemic Stroke or Transient Ischemic Attack
Stroke 43:1058-1066, Geeganage,C.M.,et al, 2012
Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA: A Meta-Analysis
Stroke 39:1358-1363, Verro,P.,et al, 2008
Dipyridamole for Preventing Stroke and Other Vascular Events in Patients With Vascular Disease: An Update
Stroke 39:1397-1398, De Schryver,E.L.L.M.,et al, 2008
Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events
Stroke 36:162-168, Leonardi-Bee,J.,et al, 2005
Efficacy of Aspirin Plus Extended-Release Dipyridamole in Preventing Recurrent Stroke in High-Risk Populations
Arch Neurol 62:403-408, Sacco, R.L., et al, 2005
Aspirin Should be First-Line Antiplatelet Therapy in the Secondary Prevention of Stroke
Stroke 33:2137-2139, Warlow,C., 2002
Update on Antiplatelet Therapy for Stroke Prevention
Arch Int Med 160:1579-1582, Sacco,R.L.& Elkind,M.S., 2000
Secondary Prevention after Cerebral Ischaemia of Presumed Arterial Origin:Is Aspirin Still the Touchstone?
JNNP 66:557-559, Algra,A.,et al, 1999
Antiplatelet Therapy:Views from the Experts
Neurol 53:S32-S37, Easton,J.D.,et al, 1999
Antithrombotic Therapy in Cerebrovascular Disease
Ann Int Med 115:885-895, Rothrock,J.F.&Hart,R.G., 1991